A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre
A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc., active.
Overview
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) is a phase 3 interventional study registered as NCT06018337 by DualityBio Inc., with 541 participants enrolled, started 2024-01-18. Conditions listed: Metastatic Breast Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Phase
Phase 3
Sponsor
DualityBio Inc.
Registry
Enrolled
541